-
A MULTIDIMENSIONAL FRAMEWORK TO MANAGE REGIONAL STRATEGIC PLANNING FOR ADVANCED THERAPY MEDICINAL PRODUCTS
Aug 11, 2026, 17:15 PM -
COST-UTILITY ANALYSIS OF ARTIFICIAL INTELLIGENCE SOFTWARE TO HELP DETECT AND CHARACTERISE COLORECTAL POLYPS
Aug 11, 2026, 17:15 PM -
FROM EVIDENCE SYNTHESIS TO ADAPTIVE TRIALS: IS EU-HTA READY FOR BAYESIAN METHODS?
Aug 11, 2026, 17:15 PM -
PRE-DELIBERATIVE CONTESTABILITY FOR AI IN HEALTH TECHNOLOGY ASSESSMENT: CLOSING THE GOVERNANCE GAP AT THE AI-HTA INTERSECTION
Aug 11, 2026, 17:15 PM -
DISCONNECTION BETWEEN SYMPTOM FREQUENCY, BURDEN, AND PATIENT PRIORITIES FOR DELAYING MULTIPLE SCLEROSIS PROGRESSION: A MULTINATIONAL QUALITATIVE STUDY
Aug 11, 2026, 17:15 PM -
COMMUNITY PHARMACY-BASED SCREENING FOR ASYMPTOMATIC ATRIAL FIBRILLATION USINGMOBILE SIX-LEAD ECG: PRELIMINARY FINDINGS
Aug 11, 2026, 17:15 PM -
COST-EFFECTIVENESS ANALYSIS OF RAPID MULTIPLEX PCR TESTING FOR PNEUMONIA MANAGEMENT
Aug 11, 2026, 17:15 PM -
REAL-WORLD FIRST-LINE TREATMENT (TX) PATTERNS IN ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI)-EXPERIENCED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) BY RACE/ETHNICITY AND AREA-LEVEL SOCIOECONOMIC STATUS (SES) IN THE US
Aug 11, 2026, 17:15 PM -
SPECIALIZED RETRIEVAL-AUGMENTED GENERATION VERSUS A STANDALONE LARGE LANGUAGE MODEL FOR MARKET ACCESS QUESTIONS ON DRUG EVALUATION: A BENCHMARK AGAINST FRENCH TRANSPARENCY COMMITTEE OPINIONS
Aug 11, 2026, 17:15 PM -
NAXITAMAB FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY HIGH-RISK NEUROBLASTOMA - A COST-EFFECTIVENESS ANALYSIS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
Aug 11, 2026, 17:15 PM -
MIXED EFFECT MODEL FOR ASSESSMENT OF TREATMENT EFFECTS WITH MISSING DATA
Aug 11, 2026, 17:15 PM -
COMPARATIVE EFFICACY AND SAFETY OF THREE CHINESE PERTUZUMAB BIOSIMILARS VERSUS REFERENCE PERTUZUMAB IN HER2-POSITIVE BREAST CANCER
Aug 11, 2026, 17:15 PM -
INFORMING SURGICAL DECISION-MAKING THROUGH EVIDENCE: A RANDOMIZED TRIAL-BASED COST-UTILITY ANALYSIS OF PERIACETABULAR OSTEOTOMY PLUS ARTHROSCOPY FOR HIP DYSPLASIA
Aug 11, 2026, 17:15 PM -
CULTURAL ADAPTATION OF THE EQ-5D-Y-5L INTO AMHARIC AND TIGRINYA LANGUAGES IN ETHIOPIA
Aug 11, 2026, 17:15 PM -
AUTOMATING BRIEFING BOOK DEVELOPMENT FOR MAJOR EUROPEAN HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS USING GENERATIVE AI
Aug 11, 2026, 17:15 PM -
COST-EFFECTIVENESS OF IVUS-GUIDED ULTRA-LOW CONTRAST PCI IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE ACROSS THREE EUROPEAN COUNTRIES
Aug 11, 2026, 17:15 PM -
CHRONIC KIDNEY DISEASE SCREENING AMONG PATIENTS TREATED FOR TYPE 2 DIABETES AND/OR HYPERTENSION IN GREECE: NATIONWIDE REAL-WORLD EVIDENCE FROM THE ELECTRONIC PRESCRIPTION SYSTEM
Aug 11, 2026, 17:15 PM -
ECONOMIC VALUE OF TREATING AND REDUCING THE BURDEN OF ATOPIC DERMATITIS AND COMORBID ASTHMA IN PAEDIATRIC PATIENTS USING DUPILUMAB: A DUTCH SOCIETAL COST-CONSEQUENCE ANALYSIS
Aug 11, 2026, 17:15 PM -
UNDERSTANDING THE BURDEN OF MYELOFIBROSIS: A LITERATURE REVIEW OF EPIDEMIOLOGY AND NATURAL HISTORY TO INFORM VALUE ASSESSMENT
Aug 11, 2026, 17:15 PM -
POPULATION-LEVEL IMPACT OF POLATUZUMAB AND GLOFITAMAB IN ALGERIA: A 15-YEAR PROJECTION
Aug 11, 2026, 17:15 PM
